MRS, Myriad align womens imaging technologies
Myriad Genetics has entered into an agreement with Mammography Reporting System (MRS) to help increase the identification of patients at high risk for hereditary breast cancer.

Under the terms of the agreement, the Seattle-based MRS will incorporate “risk flags” for hereditary breast cancer risk in its breast cancer tracking software, allowing medical professionals at mammography screening centers throughout the country to identify patients who would benefit from hereditary breast cancer testing using Myriad’s BRACAnalysis breast cancer predisposition test.

The Salt Lake City-based Myriad said its BRACAnalysis is a predictive diagnostic test to assess a woman’s risk of developing breast or ovarian cancer based on detection of mutations in the BRCA1 and BRCA2 genes.